B7-H3 Cancer Therapy Market Poised for Growth Driven by Pipeline Expansion
The market for B7-H3-targeted cancer therapies is projected to grow significantly by 2036, fueled by an expanding pipeline of treatments and increasing recognition of B7-H3 as a viable therapeutic target.
The market for therapies targeting the B7-H3 protein is expected to experience robust growth through 2036, according to a report by DelveInsight. This expansion is driven by the increasing interest in B7-H3 (CD276) as a therapeutic target, particularly for solid tumors where it is highly expressed.
B7-H3's broad expression across various cancers, including lung, prostate, and breast cancer, coupled with its limited presence in normal tissues, makes it an attractive target for precision oncology. The development of new therapies, such as Daiichi Sankyo's Ifinatamab deruxtecan (I-DXd) and MacroGenics' MGC018, is contributing to this market growth.
DelveInsight's analysis covers key markets including the US, EU4 countries, the UK, and Japan, projecting market size from 2022 to 2036. The United States represented the largest market share in 2025. The report also identifies patient populations for indications like prostate cancer, small cell lung cancer, and breast cancer.
Numerous companies, including Daiichi Sankyo, MacroGenics, Sunho Biologics, and GSK, are advancing B7-H3-targeted therapies, including antibody-drug conjugates (ADCs). These therapies aim to deliver potent cytotoxic agents directly to cancer cells. Increased investment in next-generation oncology treatments is supporting the market's potential.